Zolinza: Uses, Dosage, Demographic, Side Effects, Interactions, Generic Options Zolinza (vorinostat) is a prescription medication used for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer that affects the T-cells in the immune system. This medication is available in an oral capsule form and works by inhibiting the activity of enzymes that encourage the growth of cancer cells. Uses Zolinza is primarily used to treat CTCL in patients who have failed to respond to other forms of treatment such as radiation therapy or chemotherapy. It is also used in combination with other medications or drugs to manage other types of cancer. Dosage Zolinza is available in 100mg capsules and is typically taken once a day with food. The usual dose is 400mg daily, and treatment can continue as long as it is beneficial. Dosing may be adjusted based on a patient's age, condition, and other factors like liver function. Demographic Zolinza is approved for the treatment of CTCL in patients who have failed other therapies. According to the National Cancer Institute, CTCL affects approximately 1,500 people in the United States each year, and it is more common in adults over 50 years old, particularly in men. Side Effects Like all drugs, Zolinza can cause side effects. The most common side effects include fatigue, nausea, vomiting, fever, decreased appetite, and diarrhea. Other side effects may include headache, rash, dry skin, and weight loss. If these side effects persist or become severe, patients should consult their physicians immediately. Interactions There are certain medications that may interact with Zolinza. Patients should inform their doctor of all medications, including vitamins and supplements, before taking Zolinza. Some medications that may interact with Zolinza include blood thinners, corticosteroids, and cholesterol-lowering medications. Generic Options Zolinza is the brand name of vorinostat and there are currently no other brand names available. However, there are generic versions of Zolinza, which are sold under the name Vorinostat. Before switching to a generic version, patients should consult with their physician to ensure the medication is appropriate for their condition. Conclusion Zolinza (vorinostat) is a prescription medication used in the treatment of cutaneous T-cell lymphoma. This medication inhibits the activity of enzymes that encourage the growth of cancer cells in the body. It is typically taken once daily with food, and patients should inform their physician of all medications before taking Zolinza. Common side effects include fatigue, nausea, vomiting, and diarrhea, and there are generic versions of the drug available under the name Vorinostat.